Table 2.

Demographic data of patients and controls.

Study groups	Parameters		Values
Treatment-naive patients	Gender (number, %)	Male	20 (80%)
		Female	5 (20%)
	Age (Years, mean ± SD)	Male	27 ± 7.33
		Female	24 ± 3.71
	Family History (number, %)	Yes	15 (60%)
		No	10 (40%)
	Education (%)	Illiterate	40%
		School	32%
		High School	24%
		University	4%
	PANNS (mean ± SD)	72.52 ± 8.47
	BPRS (mean ± SD)	51.16 ± 4.69
	Positive symptoms score (mean ± SD)	17.12 ± 3.52
	Negative symptoms score (mean ± SD)	16.84 ± 4.32
	CRP (mg/L) (mean ± SD)	11.32 ± 3.23
Medicated Patients	Gender (number, %)	Male	42 (84%)
		Female	8 (16%)
	Age (Years, mean ± SD)	Male	42.26 ± 8.42
		Female	37.33 ± 11.5
	Age at onset (Years, mean ± SD)	Male	28.36 ± 6
		Female	29 ± 3.6
	Duration (Years, mean ± SD)	Male	14.45 ± 6.8
		Female	8 ± 8.18
	Family History (number, %)	Yes	27 (54%)
		No	23 (46%)
	Education (%)	Illiterate	20%
		School	30%
		High School	44%
		University	6%
	PANNS (mean ± SD)	58.12 ± 7.87
	BPRS (mean ± SD)	33.62 ± 6.33
	Positive symptoms score (mean ± SD)	12.86 ± 3.38
	Negative symptoms score (mean ± SD)	10.68 ± 2.85
	CRP (mg/L) (mean ± SD)	5.88 ± 2.22
	Clozapine dose (mg/day) (mean ± SD)	172 ± 82.16
Controls	Gender (number, %)	Male	42 (84%)
		Female	8 (16%)
	Age (Years, mean ± SD (range))	Male	39.5 ± 8.81
		Female	41 ± 9.51
	Education (%)	Illiterate	0
		School	10%
		High School	48%
		University	42%